GlassScriptPhysician profile
Carla Ostronic
NPI 1780774091
$11,510.15
in general payments reported to CMS, 2019-2025
64 companies · $3,802 in 2025
The $3,802 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.63 · 2022: $1,356 · 2023: $3,322 · 2024: $2,956 · 2025: $3,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,283 · Education: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,282.92 |
| Education | $796.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,395.07 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,142.13 | 2022-2025 | Opdivo, Reblozyl, Breyanzi |
| Novartis Pharmaceuticals Corporation | $1,037.07 | 2022-2025 | |
| Celgene Corporation | $724.63 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $591.32 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $497.87 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $496.59 | 2022-2025 | Enhertu, Tagrisso, Lynparza |
| Pfizer INC. | $394.92 | 2022-2025 | |
| Exelixis INC. | $394.25 | 2022-2025 | Cabometyx |
| Genzyme Corporation | $369.34 | 2023-2025 | |
| Incyte Corporation | $350.71 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $288.39 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $261.82 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $225.20 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $214.55 | 2022-2024 | Enhertu, Injectafer |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $205.83 | 2022-2025 | Xpovio |
| Glaxosmithkline, LLC. | $196.83 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $196.36 | 2023-2025 | |
| Eisai INC. | $182.33 | 2021-2025 | |
| Lilly USA, LLC | $179.36 | 2022-2025 | Jaypirca, Verzenio |
| Aveo Pharmaceuticals, INC. | $167.00 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $136.85 | 2023-2025 | Tecentriq, Polivy, Columvi |
| Array Biopharma INC | $126.27 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Rigel Pharmaceuticals, INC. | $117.75 | 2022-2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $112.51 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.54 | 2022-2025 | Gilotrif |
| Telix Pharmaceuticals | $105.99 | 2024-2025 | Illuccix |
| Jazz Pharmaceuticals INC. | $100.76 | 2024-2025 | |
| Genmab U.S., INC. | $80.30 | 2024-2025 | Tivdak |
| Tersera Therapeutics LLC | $78.26 | 2024-2025 | Zoladex |
| Puma Biotechnology, INC. | $72.49 | 2022-2024 | |
| Grifols USA, LLC | $71.32 | 2023-2024 | Gamunex-C, Xembify, Thrombate III |
| Servier Pharmaceuticals LLC | $70.03 | 2022-2025 | |
| Mirati Therapeutics, INC. | $56.71 | 2024 | Krazati |
| Kyowa Kirin, INC. | $54.25 | 2023-2025 | Poteligeo |
| Emd Serono, INC. | $50.09 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $48.18 | 2022 | |
| Taiho Oncology, INC. | $45.08 | 2022-2025 | |
| Kite Pharma, INC. | $35.45 | 2022-2025 | Yescarta |
| Morphosys, US INC. | $32.46 | 2023-2024 | Monjuvi |
| Amgen INC. | $31.10 | 2022 | |
| Adc Therapeutics America, INC. | $30.86 | 2023 | |
| Sobi, INC | $30.84 | 2022-2025 | |
| Blueprint Medicines Corporation | $30.04 | 2021-2024 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $29.22 | 2025 | Provenge |
| Adaptive Biotechnologies Corporation | $27.49 | 2022 | |
| Beigene USA, INC. | $24.11 | 2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $23.64 | 2025 | Onivyde |
| Organon LLC | $23.41 | 2022 | |
| Agios Pharmaceuticals, INC. | $22.16 | 2025 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $21.74 | 2022 | |
| Pharmaessentia USA Corporation | $21.31 | 2025 | Besremi |
| Ambu INC. | $20.00 | 2022 | |
| Beone Medicines USA, INC. | $17.72 | 2025 | Brukinsa |
| Astellas Pharma US INC | $17.67 | 2025 | Vyloy |
| Menarini Silicon Biosystems, INC. | $17.14 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.82 | 2024 | Truxima |
| Sumitomo Pharma America, INC. | $15.69 | 2023 | Orgovyx |
| Springworks Therapeutics, INC. | $15.60 | 2024 | Ogsiveo |
| Legend Biotech USA INC. | $15.43 | 2025 | Carvykti |
| Blue Earth Diagnostics | $13.78 | 2025 | Posluma |
| G1 Therapeutics, INC. | $13.73 | 2023 | Cosela |
| Iovance Biotherapeutics, INC. | $8.92 | 2025 | Amtagvi |
| Pharmaand Gmbh | $4.87 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Ostronic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.